Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
SMi Systems appoints Dr Ankur Mutreja as Senior Advisor
Mutreja was previously Head of Global South Partnerships at CEPI, where he was responsible for...
STA announces new Superstars of STEM, next President
Science & Technology Australia (STA) has announced the country's next Superstars of STEM,...
UQ's UniQuest partners with global biotech company
UniQuest CEO Dr Dean Moss said the collaboration with biotech company Molecule to Medicine (MTM)...
